Pneumocystis jirovecii: a review with a focus on prevention and treatment

References

• Hawksworth DL. Responsibility in naming pathogens: the case of Pneumocystis jirovecii, the causal agent of Pneumocystis pneumonia. Lancet Infect Dis. 2007;7(1):3–5. discussion 5.
   PubMed Web of Science ®Google Scholar
• Dhami ACZ, Cermakova Z. Pneumocystis jiroveci: its history and emergence as a human pathogen. Reviews in Medical Microbiology. 2015;26(3):91–97.
   Web of Science ®Google Scholar
• Venek J, Jirovec O, Lukes J. Interstitial plasma cell pneumonia in infants. Ann Paediatr. 1953;180(1):1–21.
   PubMedGoogle Scholar
• Hughes WT, Feldman S, Aur RJ, et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36(6):2004–2009.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297(26):1419–1426.
   PubMed Web of Science ®Google Scholar
• Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–1438.
   PubMed Web of Science ®Google Scholar
• Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334(6182):519–522.
   PubMed Web of Science ®Google Scholar
• Skalski JH, Kottom TJ, Limper AH. Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal transduction. FEMS Yeast Res. 2015;15(6):6.
   Web of Science ®Google Scholar
• Sokulska M, Kicia M, Wesolowska M, et al. Pneumocystis jirovecii–from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015;114(10):3577–3585.
   PubMed Web of Science ®Google Scholar
• Pifer LL, Hughes WT, Stagno S, et al. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61(1):35–41.
   PubMed Web of Science ®Google Scholar
• Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis. 2001;32(6):855–861.
   PubMed Web of Science ®Google Scholar
• Morris A, Wei K, Afshar K, et al. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis. 2008;197(1):10–17.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Baggett HC, Brooks WA, Pneumonia Etiology Research for Child Health Study G. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757–779.
   PubMed Web of Science ®Google Scholar
• GeorgeP M, Gingo MR, Morris A. Pneumocystis (carinii) jirovecii. Antimicrobe. Published 2015. [cited 2020 Dec]. Available from: http://www.antimicrobe.org/f11.asp
   Google Scholar
• Kofteridis DP, Valachis A, Velegraki M, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother. 2014;20(7):412–416.
   PubMed Web of Science ®Google Scholar
• Hosseini-Moghaddam SM, Shokoohi M, Singh G, et al. A multicenter case-control study of the effect of acute rejection and cytomegalovirus infection on Pneumocystis pneumonia in solid organ transplant recipients. Clin Infect Dis. 2019;68(8):1320–1326.
   PubMed Web of Science ®Google Scholar
• Mecoli CA, Saylor D, Gelber AC, et al. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol. 2017;35(4):671–673.
   PubMed Web of Science ®Google Scholar
• Wei KC, Sy C, Wu SY, et al. Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients. Sci Rep. 2018;8(1):8321.
   PubMedGoogle Scholar
• Lopez-Sanchez C, Falco V, Burgos J, et al. Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature. Medicine (Baltimore). 2015;94(12):e681.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–782.
   PubMed Web of Science ®Google Scholar
• Williams KM, Ahn KW, Chen M, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016;51(4):573–580.
   PubMed Web of Science ®Google Scholar
• Wang EHZ, Partovi N, Levy RD, et al. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis. 2012;14(5):519–525.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Hirzel C, Boely E, et al. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort. Transpl Infect Dis. 2018;20(6):e12984.
   PubMed Web of Science ®Google Scholar
• Liu Y, Su L, Jiang SJ, et al. Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget. 2017;8(35):59729–59739.
   PubMedGoogle Scholar
• Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46(4):625–633.
   PubMed Web of Science ®Google Scholar
• Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204–1209.
   PubMedGoogle Scholar
• Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100(5):663–671.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Lee TF, Ruan SY, et al. Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients. Infect Drug Resist. 2019;12:1457–1467.
   PubMed Web of Science ®Google Scholar
• Schildgen V, Mai S, Khalfaoui S, et al., Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 airway cells. mBio. 5(3): e01186–01114. 2014.
   PubMed Web of Science ®Google Scholar
• Vogel M, Weissgerber P, Goeppert B, et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly. 2011;141:w13184.
   PubMed Web of Science ®Google Scholar
• Fishman JA, Gans H; Practice ASTIDCo. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13587.
   PubMedGoogle Scholar
• Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR–4):1–207. quiz CE201-204.
   Google Scholar
• Alanio A, Hauser PM, Lagrou K, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2386–2396.
   PubMed Web of Science ®Google Scholar
• Marr KA, Datta K, Mehta S, et al. Urine antigen detection as an aid to diagnose invasive aspergillosis. Clin Infect Dis. 2018;67(11):1705–1711.
   PubMed Web of Science ®Google Scholar
• Tasaka S, Kobayashi S, Yagi K, et al. Serum (1 –> 3) beta-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother. 2014;20(11):678–681.
   PubMed Web of Science ®Google Scholar
• Sax PE, Komarow L, Finkelman MA, et al. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011;53(2):197–202.
   PubMed Web of Science ®Google Scholar
• Kovacs Z, Simon-Sarkadi L, Szucs A, et al. Differential effects of cold, osmotic stress and abscisic acid on polyamine accumulation in wheat. Amino Acids. 2010;38(2):623–631.
   PubMed Web of Science ®Google Scholar
• Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 1997;10(3):401–418.
   PubMed Web of Science ®Google Scholar
• Nollstadt KH, Powles MA, Fujioka H, et al. Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560. Antimicrob Agents Chemother. 1994;38(10):2258–2265.
   PubMed Web of Science ®Google Scholar
• Ricks DM, Chen K, Zheng M, et al. Dectin immunoadhesins and pneumocystis pneumonia. Infect Immun. 2013;81(9):3451–3462.
   PubMed Web of Science ®Google Scholar
• Kovacs JA, Powell F, Edman JC, et al. Multiple genes encode the major surface glycoprotein of Pneumocystis carinii. J Biol Chem. 1993;268(8):6034–6040.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–2404.
   PubMed Web of Science ®Google Scholar
• Wolfe RM, Beekmann SE, Polgreen PM, et al. Practice patterns of Pneumocystis pneumonia prophylaxis in connective tissue diseases: a survey of infectious disease physicians. Open Forum Infect Dis. 2019;6(9):ofz315.
   PubMed Web of Science ®Google Scholar
• Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS cohort study group. N Engl J Med. 1990;322(3):161–165.
   PubMed Web of Science ®Google Scholar
• Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary complications of HIV infection study group. Am J Respir Crit Care Med. 1997;155(1):60–66.
   PubMed Web of Science ®Google Scholar
• Chaiwarith R, Praparattanapan J, Nuntachit N, et al. Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV-infected patients who had CD4+ cell count <200 cells/mm(3) but undetectable plasma HIV-1 RNA: an open-label randomized controlled trial. AIDS Patient Care STDS. 2013;27(2):71–76.
   PubMed Web of Science ®Google Scholar
• D’Egidio GE, Kravcik S, Cooper CL, et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS. 2007;21(13):1711–1715.
   PubMed Web of Science ®Google Scholar
• Cervera C, Yaskina M, Kabbani D. Targeted prophylaxis to prevent late-onset Pneumocystis jirovecii pneumonia in kidney transplantation. Are we there yet? Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1619
   Google Scholar
• Wolfe RM, Peacock JE Jr. Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep. 2017;19(6):35.
   PubMed Web of Science ®Google Scholar
• Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995;151(3 Pt 1):795–799.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–1059.
   PubMed Web of Science ®Google Scholar
• Castro JG, Morrison-Bryant M. Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. HIV AIDS (Auckl). 2010;2:123–134.
   PubMedGoogle Scholar
• Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156(2):177–188.
   PubMedGoogle Scholar
• Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS treatment group. J Infect Dis. 1995;171(6):1632–1636.
   PubMed Web of Science ®Google Scholar
• Velazquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119(4):296–301.
   PubMed Web of Science ®Google Scholar
• Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74(7):730–734.
   PubMed Web of Science ®Google Scholar
• Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184(8):992–997.
   PubMed Web of Science ®Google Scholar
• Blum RN, Miller LA, Gaggini LC, et al. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. 1992;5(4):341–347. J Acquir Immune Defic Syndr (1988).
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Finkelstein DM, Spector SA, et al., A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 332(11): 693–699. 1995.
   PubMed Web of Science ®Google Scholar
• Mallolas J, Zamora L, Gatell JM, et al., Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS. 7(1): 59–64. 1993.
   PubMed Web of Science ®Google Scholar
• Souza JP, Boeckh M, Gooley TA, et al. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29(6):1467–1471.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Storer B, Nash R, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2013;27(2):521–529.
   Google Scholar
• Wozel G, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2007;21(13):194–199.
   Google Scholar
• Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob Agents Chemother. 2002;46(5):1163–1173.
   PubMed Web of Science ®Google Scholar
• Argy N, Le Gal S, Coppee R, et al. Pneumocystis cytochrome b mutants associated with atovaquone prophylaxis failure as the cause of Pneumocystis infection outbreak among heart transplant recipients. Clin Infect Dis. 2018;67(6):913–919.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. 1998;339(26):1889–1895.
   PubMed Web of Science ®Google Scholar
• Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis. 1999;180(2):369–376.
   PubMed Web of Science ®Google Scholar
• John E, Bennett RD, Blaser MJ. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 9th ed. Philadelphia, PA: Elsevier; 2020.
   Google Scholar
• Coker RJ, Clark D, Claydon EL, et al. Disseminated pneumocystis carinii infection in AIDS. J Clin Pathol. 1991;44(10):820–823.
   PubMed Web of Science ®Google Scholar
• Fichera ME, Roos DS. A plastid organelle as a drug target in apicomplexan parasites. Nature. 1997;390(6658):407–409.
   PubMed Web of Science ®Google Scholar
• Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem. 2009;44(3):937–953.
   PubMed Web of Science ®Google Scholar
• Kay R, DuBois RE. Clindamycin/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. South Med J. 1990;83(4):403–404.
   PubMed Web of Science ®Google Scholar
• Barber BA, Pegram PS, High KP. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis. 1996;23(4):718–722.
   PubMed Web of Science ®Google Scholar
• Lyman WD, Tricoche M, Hatch WC, et al. Human fetal central nervous system organotypic cultures. Brain Res Dev Brain Res. 1991;60(2):155–160.
   PubMedGoogle Scholar
• Falagas ME, Gorbach SL. Clindamycin and metronidazole. Med Clin North Am. 1995;79(4):845–867.
   PubMed Web of Science ®Google Scholar
• Owens RC Jr., Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31.
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71(9):2405–2413.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1978;92(2):285–291.
   PubMed Web of Science ®Google Scholar
• Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986;105(1):37–44.
   PubMed Web of Science ®Google Scholar
• Klein NC, Duncanson FP, Lenox TH, et al., Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 6(3): 301–305. 1992.
   PubMed Web of Science ®Google Scholar
• Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med. 1988;109(4):280–287.
   PubMed Web of Science ®Google Scholar
• Thomas M, Rupali P, Woodhouse A, et al. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41(11–12):862–868.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Aoshima M, Nakashita T, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2018;51(6):810–820.
   PubMedGoogle Scholar
• Creemers-Schild D, Kroon FP, Kuijper EJ, et al. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. Infection. 2016;44(3):291–299.
   PubMed Web of Science ®Google Scholar
• Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 study group. Ann Intern Med. 1996;124(9):792–802.
   PubMed Web of Science ®Google Scholar
• Hughes WT, LaFon SW, Scott JD, et al. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis. 1995;171(5):1295–1301.
   PubMed Web of Science ®Google Scholar
• Meyer C, Behm N, Brown E, et al. An adverse drug reaction to Trimethoprim-sulfamethoxazole revealing primary hiv: a case report and literature review. Case Rep Infect Dis. 2015;2015:691010.
   PubMed Web of Science ®Google Scholar
• Huang L, Crothers K, Atzori C, et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10(10):1721–1728.
   PubMed Web of Science ®Google Scholar
• Queener SF, Cody V, Pace J, et al. Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii. Antimicrob Agents Chemother. 2013;57(10):4990–4998.
   PubMed Web of Science ®Google Scholar
• Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS. 2005;19(8):801–805.
   PubMed Web of Science ®Google Scholar
• Valerio A, Tronconi E, Mazza F, et al. Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr. 2007;45(5):521–528.
   PubMed Web of Science ®Google Scholar
• Alvarez-Martinez MJ, Moreno A, Miro JM, et al. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis. 2008;62(1):34–43.
   PubMed Web of Science ®Google Scholar
• Montgomery AB, Feigal DW Jr., Sattler F, et al. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired immune deficiency syndrome. Am J Respir Crit Care Med. 1995;151(4):1068–1074.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr., Hollander H, Golden JA. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study. Ann Intern Med. 1987;107(4):495–498.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr., Chernoff D, Feigal DW Jr., et al. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann Intern Med. 1990;113(3):203–209.
   PubMed Web of Science ®Google Scholar
• Qiu W, Liu JJ, Carstens EB. Studies of Choristoneura fumiferana nuclear polyhedrosis virus gene expression in insect cells. Virology. 1996;217(2):564–572.
   PubMed Web of Science ®Google Scholar
• Toma E, Thorne A, Singer J, et al. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. Clin Infect Dis. 1998;27(3):524–530.
   PubMed Web of Science ®Google Scholar
• Kim T, Kim SH, Park KH, et al. Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia. J Infect Chemother. 2009;15(5):343–346.
   PubMed Web of Science ®Google Scholar
• Helweg-Larsen J, Benfield T, Atzori C, et al. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64(6):1282–1290.
   PubMed Web of Science ®Google Scholar
• Hughes W, Leoung G, Kramer F, et al., Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 328(21): 1521–1527. 1993.
   PubMed Web of Science ®Google Scholar
• Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med. 1994;121(3):174–180.
   PubMed Web of Science ®Google Scholar
• Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis. 2001;183(5):819–822.
   PubMed Web of Science ®Google Scholar
• Walker DJ, Wakefield AE, Dohn MN, et al. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J Infect Dis. 1998;178(6):1767–1775.
   PubMed Web of Science ®Google Scholar
• Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323(12):776–782.
   PubMed Web of Science ®Google Scholar
• Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother. 2001;183(5):1985–1989.
   Google Scholar
• Cushion MT, Linke MJ, Ashbaugh A, et al. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One. 2010;5(1):e8524.
   PubMed Web of Science ®Google Scholar
• Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis. 2006;431(9):e92–94.
   Google Scholar
• Kim T, Hong HL, Lee YM, et al. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis. 2013;45(6):484–488.
   PubMed Web of Science ®Google Scholar
• Armstrong-James D, Stebbing J, John L, et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax. 2011;66(6):537–538.
   PubMed Web of Science ®Google Scholar
• Wang M, Lang G, Chen Y, et al. A pilot study of echinocandin combination with trimethoprim/sulfamethoxazole and clindamycin for the treatment of AIDS patients with Pneumocystis pneumonia. J Immunol Res. 2019;2019:8105075.
   PubMed Web of Science ®Google Scholar
• Huang YS, Liu CE, Lin SP, et al. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS. 2019;33(8):1345–1351.
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36(11):1445–1457.
   PubMed Web of Science ®Google Scholar
• Huang ZB, Eden E. Effect of corticosteroids on IL1 beta and TNF alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia. Chest. 1993;104(3):751–755.
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Sattler FR, Chiu J, et al., A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 323(21): 1451–1457. 1990.
   PubMed Web of Science ®Google Scholar
• Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323(21):1444–1450.
   PubMed Web of Science ®Google Scholar
• Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015(4):CD006150.
   Google Scholar
• Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113(5):1215–1224.
   PubMed Web of Science ®Google Scholar
• Wieruszewski PM, Barreto JN, Frazee E, et al. Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest. 2018;154(3):636–644.
   PubMed Web of Science ®Google Scholar
• Lemiale V, Debrumetz A, Delannoy A, et al. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14(1):87.
   PubMedGoogle Scholar
• Fujikura Y, Manabe T, Kawana A, et al. Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in Non-HIV-infected patients: a systematic review and meta-analysis of observational studies. Arch Bronconeumol. 2017;53(2):55–61.
   PubMed Web of Science ®Google Scholar
• Ding L, Huang H, Wang H, et al. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care. 2020;10(1):34.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299–311.
   PubMed Web of Science ®Google Scholar
• Vogel MN, Vatlach M, Weissgerber P, et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol. 2012;81(6):1315–1320.
   PubMed Web of Science ®Google Scholar
• Ahmad H, Mehta NJ, Manikal VM, et al. Pneumocystis carinii pneumonia in pregnancy. Chest. 2001;120(2):666–671.
   PubMed Web of Science ®Google Scholar
• Sattler FR, Frame P, Davis R, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS clinical trials group protocol 029/031. J Infect Dis. 1994;170(1):165–172.
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Rockenbauer M, Sorensen HT, et al. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol. 2001;15(6):637–646.
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343(22):1608–1614.
   PubMed Web of Science ®Google Scholar
• Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis. 1994;170(4):912–917.
   PubMed Web of Science ®Google Scholar
• Harstad TW, Little BB, Bawdon RE, et al. Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats. Am J Obstet Gynecol. 2013;14(1):912–916.
   Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
   PubMedGoogle Scholar